AbbVie (ABBV) Getting Somewhat Positive News Coverage, Analysis Finds

Press coverage about AbbVie (NYSE:ABBV) has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. AbbVie earned a daily sentiment score of 0.17 on Accern’s scale. Accern also gave headlines about the company an impact score of 46.7158338082093 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Here are some of the news headlines that may have effected Accern Sentiment Analysis’s rankings:

AbbVie (ABBV) traded down $1.22 during mid-day trading on Friday, hitting $113.71. 8,879,276 shares of the company were exchanged, compared to its average volume of 6,703,521. The company has a debt-to-equity ratio of 6.07, a quick ratio of 1.18 and a current ratio of 1.28. AbbVie has a 1-year low of $63.12 and a 1-year high of $125.86. The firm has a market cap of $181,360.00, a PE ratio of 20.53, a PEG ratio of 1.12 and a beta of 1.52.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, January 26th. The company reported $1.48 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.44 by $0.04. AbbVie had a net margin of 18.82% and a return on equity of 158.15%. The business had revenue of $7.74 billion for the quarter, compared to analysts’ expectations of $7.53 billion. During the same quarter last year, the company earned $1.20 EPS. The company’s revenue for the quarter was up 13.9% compared to the same quarter last year. analysts expect that AbbVie will post 7.48 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, May 15th. Investors of record on Friday, April 13th will be issued a $0.96 dividend. This represents a $3.84 dividend on an annualized basis and a dividend yield of 3.38%. The ex-dividend date is Thursday, April 12th. This is a boost from AbbVie’s previous quarterly dividend of $0.71. AbbVie’s dividend payout ratio (DPR) is 51.26%.

AbbVie announced that its board has authorized a share buyback program on Thursday, February 15th that permits the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization permits the company to buy shares of its stock through open market purchases. Shares repurchase programs are generally an indication that the company’s leadership believes its shares are undervalued.

A number of research analysts have commented on ABBV shares. BMO Capital Markets downgraded shares of AbbVie from a “market perform” rating to an “underperform” rating and reduced their price objective for the company from $125.86 to $84.00 in a research note on Monday, January 29th. They noted that the move was a valuation call. Zacks Investment Research downgraded shares of AbbVie from a “buy” rating to a “hold” rating in a research report on Monday, January 22nd. Credit Suisse Group set a $98.00 price target on shares of AbbVie and gave the stock a “hold” rating in a research report on Monday, January 22nd. Piper Jaffray Companies restated a “buy” rating on shares of AbbVie in a research report on Tuesday, January 2nd. Finally, SunTrust Banks raised their price target on shares of AbbVie to $157.00 and gave the stock an “average” rating in a research report on Monday, January 29th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, eight have given a buy rating and two have given a strong buy rating to the stock. AbbVie currently has an average rating of “Buy” and a consensus target price of $120.96.

In related news, SVP Timothy J. Richmond sold 87,040 shares of the stock in a transaction dated Monday, December 18th. The shares were sold at an average price of $98.45, for a total value of $8,569,088.00. Following the sale, the senior vice president now owns 113,118 shares of the company’s stock, valued at approximately $11,136,467.10. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Carlos Alban sold 83,574 shares of the stock in a transaction dated Thursday, March 1st. The stock was sold at an average price of $114.49, for a total transaction of $9,568,387.26. Following the completion of the sale, the executive vice president now directly owns 133,026 shares in the company, valued at approximately $15,230,146.74. The disclosure for this sale can be found here. In the last ninety days, insiders sold 298,237 shares of company stock worth $33,154,663. Corporate insiders own 0.23% of the company’s stock.

TRADEMARK VIOLATION WARNING: “AbbVie (ABBV) Getting Somewhat Positive News Coverage, Analysis Finds” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another publication, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this report can be read at

About AbbVie

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Insider Buying and Selling by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with's FREE daily email newsletter.

Leave a Reply